Arthur Allen - Kaiser Health News

After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?

The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for COVID. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.

A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.

An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.

As scientists argue whether a previous bout of COVID-19 voffers the same amount of protection as vaccinations, people turn to the courts to decide.

A CDC advisory committee is set to discuss a possible link between the vaccine and heart-related side effects in youths, and whether it merits changing recommendations for vaccinating teenagers.

President Biden has ordered intelligence agencies to determine where the coronavirus originated, but China is bucking demands to let investigators see more. Can this probe lead to anything positive?

Leading virologists, including Dr. Anthony Fauci, are demanding a deeper probe into China’s Wuhan Institute of Virology as they try to identify the source of the deadly coronavirus.

President Biden has said he plans to invoke the Defense Production Act to provide more COVID vaccines, but forcing companies to gear up production won’t provide much-needed doses anytime soon.

Drugmakers will walk away with with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.